NeoPhore

Cambridge, England, United Kingdom

+44 (0)1223 804250 ★

http://www.neophore.com/

Company profile

NeoPhore company profile

NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.

Business identity

Website: http://www.neophore.com/
Contact email: [email protected]
Phone number: +44 (0)1223 804250
Operating status: Active
Company type: For Profit
Employee range: 00001-00010 employees
Revenue range: $1K+
Founded: 2017-11-01

LinkedIn X

Headquarters

Headquarters: Cambridge, England, United Kingdom
Postal code: CB22 3AT
Country code: GB
Continent: Europe

Capital profile

Funding and company signals

Funding stage: Early Stage Venture
Funding rounds: 6
Total equity funding: $44.7M
Last funding: Series B / 2024-05-22
Last equity funding: Series B
Investors: 11
Lead investors: 4
Founders: 1
Articles: 35

Categories and groups

Biotechnology Simulation Therapeutics Translation Service Biotechnology Health Care Professional Services Science and Engineering Software

Founders and investors

Founders

Alberto Bardelli

Lead investors

Bristol-Myers SquibbClaris VenturesInnovate UKSixth Element Capital

Investors

3B Future Health FundBristol-Myers SquibbClaris VenturesInnovate UKNeva SGR

People at this company

Preview only. Contact details are available after you sign in.

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Shipment records and coverage can change as the dataset is updated.